ClinicalTrials.gg
Active, not recruitingNCT07251465Updated Oct 27, 2026

A Study to Learn How Effective is PCV20 to Help Stop Adults Who Have a Higher Chance of Getting Pneumonia

An observational study in Community-Acquired Pneumonia (CAP), sponsored by Pfizer. Active, not recruiting at 1 site in United States. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Pfizer · Observational

How we know

Updated Oct 27, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
846,279
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Community-Acquired Pneumonia by Pfizer — none open to participants now, 2 under way, none of them phase 3. Community-Acquired Pneumonia · Pfizer.

Started
2026
the only one that year
Observational
7 of 14
none open now
Registered
14th of 14
by date

Among the 14 studies in Community-Acquired Pneumonia by Pfizer, this one is the only one that started in 2026, is one of 7 observational ones, and was the 14th registered.

Community-Acquired Pneumonia

325 studies on the registry are indexed under Community-Acquired Pneumonia; 77 are open to participants now.

Browse Community-Acquired Pneumonia studies →

Open to participants now

None of the 14 studies in Community-Acquired Pneumonia by Pfizer is open now. The open studies under Community-Acquired Pneumonia, anywhere →

Who these studies take

Of the 41 Community-Acquired Pneumonia studies recruiting now, 29 (71%) set no upper age limit and 9 (22%) stop at 75 or younger; 13 take children under 18; 5 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Community-Acquired Pneumonia by Pfizer as a file.
02

Study summary

The purpose of this study is to learn how well PCV20 stops adults from getting community-acquired pneumonia. Pneumonia is an infection of the lungs that can be caused by germs like bacteria, virus, or fungi. This study uses existing healthcare information. No participants will be actively enrolled. The information of participants will be taken from Kaiser Permanente Southern California's (KPSC) electronic health records (EHR).

We will look at the EHR information for adults who meet the following points:

  • 19 years of age or older and a KPSC member between 01 July 2022 and 31 May 2025.
  • have higher risk of pneumococcal disease due to older age or a chronic medical condition
  • have been a KPSC member for the year before joining the study and for at least one year before 01 July 2022.
  • have not received PCV15, PCV21, PPSV23 (2 years before), or PCV13 (5 years before) joining the study.
  • have not received PCV20 before 01 June 2022.
  • have not received PCV20 before turning 65 or before having a chronic medical condition which has higher risk of pneumococcal disease.
  • have had at least one outpatient visit.
  • have not had pneumonia or lower respiratory tract infection within 30 days of joining the study.

The study will begin on 01 July 2022 and end on 30 June 2025. At the end of the follow-up period, the study will compare the number of community-acquired pneumonia cases among people who did and did not receive PCV20.

03

Conditions studied

  • Community-Acquired Pneumonia (CAP)

Keywords

  • Respiratory tract infections
  • Vaccines
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study will include a cohort of adults 19-64 years of age with at least one medical or behavioral risk factor associated with an increased risk of pneumococcal disease and a cohort of adults ≥65 years of age. Individuals who meet the eligibility criteria as of 01 July 2022 or who become eligible during the cohort identification period (01 July 2022 through 31 May 2025) will be included in the study. Individuals could contribute to both the 19-64 and ≥65 years of age cohorts if the individual met the inclusion and exclusion criteria for each respective cohort. Follow-up time will be classified by PCV20 exposure status. Within each cohort (19-64, ≥65 years), individuals can contribute one PCV20-unvaccinated time-segment, one PCV20-vaccinated time-segment, or both.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

19-64 years of age cohort 1. Aged ≥19 at some point between July 1, 2022 and May 31, 2025 with 1-year continuous membership prior to July 1, 2022 2. At least 1 year of continuous enrollment as a KPSC member prior to the index date, allowing for 45-day administrative gaps 3. Age 19-64 years of age on the index date with ≥1 medical condition or risk factor identified during the 1-year continuous enrollment period prior to the index date 4. At least one outpatient visit prior to the index date

  • 65 years cohort

    1. Aged ≥19 at some point between July 1, 2022 and May 31, 2025 with 1-year continuous membership prior to July 1, 2022
    2. ≥1 year of continuous enrollment as a KPSC member prior to the index date, allowing for 45-day administrative gaps
    3. Age ≥65 years on the index date
    4. At least one outpatient visit prior to the index date

Exclusion criteria

Exclusion Criteria:

19-64 years of age cohort

<!-- -->

  1. Received PCV20 prior to June 1, 2022, turning age 19 years, or meeting the medical condition or behavioral risk factor inclusion criteria
  2. Vaccinated index date is >30 days after the first PCV20 vaccination date or >1 dose of PCV20 is received \<30 days prior to the index date
  3. Received PCV15 or PCV21 prior to the index date
  4. Received PPSV23 ≤2 years prior to the index date
  5. Received PCV13 ≤5 years prior to the index date
  6. Outcome-related diagnosis code in the EHR \<30 days prior to the index date
  • 65 years cohort

    1. Received PCV20 prior to June 1, 2022 or prior to turning ≥65 years of age
    2. Vaccinated index date is >30 days after the first PCV20 vaccination date or >1 dose of PCV20 is received \<30 days prior to the index date
    3. Received PCV15 or PCV21 prior to the index date
    4. Received PPSV23 ≤2 years prior to the index date
    5. Received PCV13 ≤5 years prior to the index date
    6. Outcome-related diagnosis code in the EHR \<30 days prior to the index date
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
846,279 participants (actual)
Patient registry
No
Biospecimen retention
None retained

Groups and cohorts

  • Adults ≥19-64 years old with medical conditions and behavioral risk factors

    For the 19-64 years of age cohort, the unvaccinated index date is the earliest day during the cohort identification period when the individual is 19-64 years of age, has ≥1 year of prior continuous enrollment, and has a medical or behavioral risk factor during the prior 1-year continuous enrollment period. The vaccinated index is the day during the cohort identification period that is 30 days after PCV20 vaccination received when the individual has ≥1 year of prior continuous enrollment, is 19-64 years of age, and has a risk factor identified during the prior 1-year continuous enrollment period.

    Biological: Receipt of PCV20

  • Adults ≥65 years old

    For the ≥65 years of age cohort, the unvaccinated index date is the earliest day between 01 July 2022 and 31 May 2025 (cohort identification period) when the individual is ≥65 years of age and has ≥1 year of prior continuous enrollment. The vaccinated index date is the date during the cohort identification period that is 30 days after PCV20 vaccination received when the individual is ≥65 years of age and has ≥1 year of prior continuous enrollment.

    Biological: Receipt of PCV20

Interventions

  • BiologicalReceipt of PCV20

    The main exposure of interest will be receipt of PCV20.

06

What researchers measure

Primary outcomes

  1. PCV20 vaccine effectiveness (VE) against all-cause pneumonia (ACP) separately among both adults 19-64 years of age with medical conditions and behavioral risk factors and among adults ≥65 years of age

    PCV20 VE against ACP calculated as (1-aHR) × 100% separately among adults aged 19-64 years with medical conditions or behavioral risk factors and among adults ≥65 years of age

    Time frame: 3 years

Secondary outcomes

  1. Incidence rates calculated separately among adults 19-64 years of age with medical conditions or behavioral risk factors and among adults ≥65 years of age

    Unweighted and unadjusted incidence rates will be calculated as the number of ACP episodes per 100,000 person-years overall and separately for PCV20-vaccinated and unvaccinated time-segments. Incidence rates will be calculated separately among adults 19-64 years of age with medical conditions or behavioral risk factors and among adults ≥65 years of age

    Time frame: 3 years

  2. Absolute rate reduction of ACP associated with PCV20 vaccination calculated separately among adults 19-64 years of age with medical conditions or behavioral risk factors and among adults ≥65 years of age

    Absolute rate reduction of ACP associated with PCV20 vaccination will be calculated using the weighted VE estimate from the Cox proportional hazards model along with the non-model based unadjusted incidence rate (IR) during PCV20-vaccinated follow-up time. Absolute rate reduction will be calculated separately among adults 19-64 years of age with medical conditions or behavioral risk factors and among adults ≥65 years of age.

    Time frame: 3 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jan 2026 (actual). Primary completion is estimated for Nov 2026, 9 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Sep 2026 → Nov 2026 and completion Sep 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2025
First posted
Nov 26, 2025
StartActual
Jan 21, 2026
Primary completionEst.
Nov 15, 2026was Sep 2026
CompletionEst.
Nov 15, 2026was Sep 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 30, 2026→Nov 15, 2026
Oct 27, 2026
Study completion
Sep 30, 2026→Nov 15, 2026
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Primary completion Sep 30, 2026→Nov 15, 2026
    Study completion Sep 30, 2026→Nov 15, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07251465
Lead sponsor
Pfizer
Collaborators
Kaiser Permanente
Responsible party
Sponsor
First posted
Nov 26, 2025
Start date
Jan 21, 2026
Primary completion
Nov 15, 2026 (estimated)
Completion
Nov 15, 2026 (estimated)
Last update
Oct 27, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion